Click on a filter below to refine your search. Remove a filter to broaden your search.
Despite patient beliefs, no effect was seen on the severity or duration of the cough.
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
During high-concentration capsaicin patch treatment, a significant decrease was seen in average daily morphine equivalent dose.
Caps are associated with a reduction in insulin costs, mainly driven by patients enrolled in health savings accounts.
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
The findings seen among adults of all ages, especially those aged 85 years or older; the risk was highest in the first 28 days after initiation.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.